SAN DIEGO, June 5, 2017 /PRNewswire/ — NuVasive, Inc. (NASDAQ: NUVA), a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced the PRECICE® system and PRECICE UNYTE™ platform from NuVasive Specialized Orthopedics (NSO) are featured in the June 2017 supplement of the Journal of Orthopaedic Trauma (JOT), which demonstrates a lower complication rate, greater patient comfort and faster healing in comparison to traditional treatments1.
NSO, a NuVasive division focused on the design and innovation of disruptive orthopedic solutions, developed a proprietary platform of magnetically adjustable implant systems that include:
- The PRECICE system is an intramedullary device that once implanted utilizes an External Remote Controller (ERC) to non-invasively lengthen the femur and tibia. Through propriety magnetic technology, the PRECICE ERC lengthens the PRECICE device with precision rate control. Each patient’s lengthening is customized based on a physician directed program.
- PRECICE UNYTE is an intramedullary solution for stabilizing and treating difficult to heal fractures and non-unions. It leverages clinically validated technology based on the proven principles of compression and distraction osteogenesis and uses the ERC magnetic technology to apply non-invasive customized treatment for proper bone healing and restoring natural bone length.
“Our groundbreaking, non-invasive technology platforms from NSO have disrupted the spine and orthopedic markets,” said Gregory T. Lucier, NuVasive chairman and chief executive officer. “The positive outcomes from our early clinical experience with PRECICE UNYTE demonstrate that we are able to treat complex fractures with our magnetic technology, which will help transform the lives of patients that previously lacked a formidable solution.”
PRECICE system and PRECICE UNYTE are featured in the June JOT Supplement, “Intramedullary Limb Lengthening and Compression for Orthopedic Trauma Surgeons“, with five articles authored by leading surgeons Robert Rozbruch, M.D., Mitchell Bernstein, M.D., Stuart Green, M.D., Austin Fragomen, M.D., and Tracy Watson, M.D.
“I’m honored to report on the success of PRECICE UNYTE intramedullary compression implant and share the positive results of our early clinical experience,” said Dr. Green, University of California, Irvine, Department of Orthopaedic Surgery. “The future of this technology is clearly evident in the JOT supplement, which highlights the key role engineering research plays in developing medical device innovation. Patients around the globe will greatly benefit from the new technology created by the collaboration effort of NSO and the surgeon community.”
PRECICE UNYTE WEBINAR
The Company is hosting a webinar on June 6, 2017 titled, “Treating Challenging Fractures and Nonunions,” featuring Austin Fragomen, M.D. from the Hospital for Special Surgery, New York. The webinar will look at traditional treatment options and highlight new technologies in intramedullary compression and distraction devices. Click here for more information and to register.
NuVasive, Inc. (NASDAQ: NUVA) is a world leader in minimally invasive, procedurally-integrated spine solutions. From complex spinal deformity to degenerative spinal conditions, NuVasive is transforming spine surgery and beyond with innovative technologies designed to deliver reproducible and clinically proven surgical outcomes. NuVasive’s highly differentiated, procedurally-integrated solutions include access instruments, implantable hardware and software systems for surgical planning and reconciliation technology that centers on achieving the global alignment of the spine. With $962 million in revenues (2016), NuVasive has an approximate 2,300 person workforce in more than 40 countries around the world. For more information, please visit www.nuvasive.com.
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products (including the iGA™ platform), the Company’s ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
1 Fragomen, Austin T. J Orthop Trauma; Volume 31, Number 6 Supplement, June 2017; S7-S13
SOURCE NuVasive, Inc.